Table 1 A selected list of glaucoma drugs in late-stage clinical trails
From: Drug discovery in ophthalmology: past success, present challenges, and future opportunities
Drug name | Company | Mechanism of action | Clinical phase | Clinical trial identifier | Ref |
|---|---|---|---|---|---|
Vesneo | Bausch & Lomb and Nicox | Nitric-oxide-donating prostaglandin F2a analogue | Phase III | NCT01749930 NCT01895972 NCT01749904 | [43] |
Trabodenoson | Inotek Pharmaceuticals | Adenosine receptor agonist | Entering Phase III in end 2015 | NCT02565173 | [103] |
Rhopressa | Aerie Pharmaceuticals | Inhibits Rho Kinase (ROCK), and the norepinephrine transporter (NET) | Phase III | NCT02246764 NCT02207621 NCT02207491 NCT02558374 | [104] |
Rocla tan | Aerie Pharmaceuticals | Combination of Rhopressa and latanoprost | Phase III | NCT02558400 | [105] |
Bamosiran | Sylentis | Small interference RNA (siRNA) inhibitor of beta 2 adrenergic receptor | Phase II | NCT02250612 | [44] |
Latanoprost punctal plug delivery system (L-PPDS) | Mati Therapeutics Inc | Sustained delivery of latanoprost via a punctal plug | Phase II | NCT02014142 NCT01481051 NCT01481077 NCT00820300 NCT00845299 NCT01229982 NCT00821002 NCT00967811 NCT 01037036 | [45] |